July 17, 2019 DURB Meeting Summary

Issue	Action	Notes
Roll Call		Present: Dr. Swee, Dr. Gochfeld, Dr. Moynihan, Dr. Marcus, Ms. Olson, Dr. Barberio, Dr. Gooen, Mr. Schafer, Dr. Lind (ex-officio) Unable to attend:, Dr. Moore
Public Notice		Dr. Swee read the notice required for public meetings: In compliance with Chapter 231 of public laws of 1975, notice of this meeting was given by way of filings in the Trenton Times, Star Ledger and Atlantic City Press.
Review of Minutes	Approved	Minutes from April 17, 2019 meeting was reviewed and approved. The approved meeting summary will also be posted on the DURB website at: http://nj.gov/humanservices/dmahs/boards/durb/meeting/index.html
Secretary's Report		• The Commissioners have signed off on the following DURB-recommended protocols: - Prescription opioids - Pregabalin (Lyrica®) - Cannabidiol (Epidiolex®) DXC's MEP is working on implementing these protocols. • The Office Based Addiction Treatment (OBAT) newsletter was emailed to the Board members as promised during the last meeting. • Ed Vaccaro, R.Ph., explained the recently implemented (July 1st, 2019) Risk Corridor Drugs concept to the Board members. The State will share the risk in the utilization of about 57 high cost drugs with the Managed Care Organizations (MCOs). The list will be updated periodically. - Hemophilia drugs are excluded from the risk corridor drugs list. - Sickle cell drugs are included in the list • The DURB Annual Report for fiscal year 2018 was published in the NJ Register on Monday, July 15. They will be accepting public comments thru September 13, 2019.

July 17, 2019 DURB Meeting Summary

Issue	Action	Notes
Old Business		
WellCare's List of "Other Category" Contents in the PA Denials Report		The Board reviewed a report provided by WellCare to explain a breakdown of the "other category" in the Prior Authorization Denial Report. The Board requested further details of the explanations (numbers) for some of the items listed in the submitted report. Ashraf Sunesara, PharmD, with WellCare expressed concern that his Plan's system may not be able to produce the Board's request but promised to work with his team to obtain the information. The Board requested similar information from Ms. Connie Yuen, R.Ph., with Amerigroup.
New Business		
(A) Proposed Protocol for Hereditary Angioedema products	Approved	The Board reviewed a proposed protocol for Hereditary Angioedema (HAE) products. Dr. Swee requested cost data on the products as education for the Board members. He was informed that the State spends about eight million dollars a year on this drug class. The Board approved the protocol.
(B) Proposed Protocol for Urea Cycle Disorder Products	Approved pending comments from expert	The Board reviewed a proposed protocol for Urea Cycle Disorder products. Dr. Marcus informed the Board that he had sent a copy of the protocol to geneticist at Rutgers, New Jersey Medical School for review and comments. The Board approved the protocol pending comments from the geneticist which could then be used to amend the protocol at a later time.
(C) Proposed Protocol for Chelating Agents	Approved with suggested changes	The Board reviewed a proposed protocol for chelating agents (Cuprimine® [penicillamine] and Syprine® [trientine]). They requested that the title of the protocol should be changed to reflect the specific disease states for which these products will be used (Wilson's disease, cystinuria, severe rheumatoid arthritis). They approved the protocol pending these changes.
(D) Proposed Protocol for Zolgensma® (onasemnogene abeparvovec-xioi)	Approved with suggested changes	The Board reviewed a proposed protocol for Zolgensma®, a product approved by the FDA for the treatment of spinal muscular atrophy (SMA) in patients less than 2 years of age. They approved the protocol with a recommendation to change the specialty consult to "pediatric neurologist or geneticist".

July 17, 2019 DURB Meeting Summary

<table>
<tr><th>Issue</th><th>Action</th><th>Notes</th></tr>
<tr><td>Informational Highlights/Reports</td><td></td><td></td></tr>
<tr><td>1. Fee-for-Service/MCO Prior Authorization Report</td><td>Continue to monitor.</td><td>The Board reviewed prior authorization (PA) denial report comparing all MCO plans including FFS for the 1th quarter of 2019. Mr. Schafer wanted to know if denials for "clinical criteria not met" were absolute. Kevin McCloy, PharmD, with Horizon promised to provide that information if available at the next meeting.
Percentage of prior authorization requests relative to total claims and denials associated with the PAs are listed below:

<table>
<tr><td>Plan</td><td>(%) PA Requests of claims</td><td>Denial (%)</td></tr>
<tr><td>FFS</td><td>0.6</td><td>14</td></tr>
<tr><td>Aetna</td><td>0.7</td><td>33</td></tr>
<tr><td>Amerigroup</td><td>1</td><td>27</td></tr>
<tr><td>Horizon</td><td>1</td><td>36</td></tr>
<tr><td>UHC</td><td>0.9</td><td>52</td></tr>
<tr><td>WellCare</td><td>0.6</td><td>47</td></tr>
</table>
</td></tr>
<tr><td>2. Summary of DURB Actions/Recommendations</td><td></td><td>The Board reviewed a summary of actions from previous meetings (July 2018 thru April 2019).</td></tr>
<tr><td>3. DHS/DHSS/MCO Programs Top Drugs Report</td><td></td><td>Top drugs report for April 2019 (FFS)/March 2019 (MCOs) was reviewed.
Dr. Marcus wanted to know how to estimate the percentage of rebates included in the drugs cost. Mr. Vaccaro promised to find out if that information could be shared at a public meeting. Dalia Hanna, PharmD, with DXC Technology informed the Board of possible supplemental rebates from the drug manufacturers to the MCOs which is also shared with the State.</td></tr>
<tr><td>4. Medication Information</td><td></td><td>Some medical information was presented which included the recent angiotensin receptor blockers (ARBs) and other FDA recalls.</td></tr>
</table>

July 17, 2019 DURB Meeting Summary

Issue	Action	Notes
Follow up items:		- WellCare's pharmacy director, Ash Sunesara, PharmD, will provide further breakdown (numbers) of the "other category" in the quarterly denials report - Amerigroup's pharmacy director will also provide similar information for the Board - Ed Vaccaro, R.Ph., will inquire about drugs rebate information and how much of that could be shared with the Board at the meeting setting - Horizon's Kevin McCloy, PharmD, will provide information on absolute denials associated with the "criteria not met" category in the quarterly denials report